目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.3 DATA TRIANGULATION
2.2 MARKET ESTIMATION METHODOLOGY
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 PRIMARY INSIGHTS
2.6 RESEARCH ASSUMPTIONS
2.7 RISK ANALYSISa
2.8 RECESSION IMPACT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5. 2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 SUPPLY CHAIN ANALYSIS /VALUE CHAIN
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT
5.5.2 AVERAGE SELLING PRICE TREND ANALYSIS
5.6 REGULATORY ANALYSIS
5.6.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7 TECHNOLOGY ANALYSIS
5.8 ECOSYSTEM ANALYSIS
5.9 PORTER’S FIVE FORCES ANALYSIS
5.10 KEY CONFERENCES AND EVENTS IN 2023
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
5.12 PATENT ANALYSIS

6 CRISPR MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 CRISPR PRODUCTS
6.2.1 CRISPR ENZYMES & KITS
6.2.2 CRISPR LIBRARIES
6.2.3 OTHER PRODUCTS (DESIGN TOOLS, ANTIBODIES AND OTHER REAGENTS)
6.3 CRISPR SERVICES
6.3.1 GRNA SYNTHESIS & CELL LINE DEVELOPMENT
6.3.2 SCREENING & VALIDATION
6.3.3 OTHER SERVICES (TRANSCRIPTIONAL ACTIVATION AND EPIGENOME EDITING)

7 CRISPR MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 DRUG DISCOVERY & DEVELOPMENT
7.3 AGRICULTURE
7.4 OTHER APPLICATIONS (BIOFUELS, VETERINARY)

8 CRISPR MARKET, BY END USER
8.1 INTRODUCTION
8.2 PHARMACEUTICAL COMPANIES AND BIOTECHNOLOGY COMPANIES
8.3 ACADEMIC AND RESEARCH INSTITUTES
8.4 OTHERS (CROS & CDMOS)

9 CRISPR MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.2.3 RECESSION IMPACT
9.3 EUROPE
9.3.1 GERMANY
9.3.2 ITALY
9.3.3 FRANCE
9.3.4 UK
9.3.5 SPAIN
9.3.6 REST OF EUROPE
9.3.7 RECESSION IMPACT
9.4 ASIA PACIFIC
9.4.1 CHINA
9.4.2 JAPAN
9.4.3 INDIA
9.4.4 REST OF APAC
9.4.5 RECESSION IMPACT
9.5 LATIN AMERICA
9.5.1 BRAZIL
9.5.2 REST OF LATAM
9.5.3 RECESSION IMPACT
9.6 MIDDLE EAST AND AFRICA
9.6.1 RECESSION IMPACT

10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 STRATEGIES ADOPTED BY KEY PLAYERS
10.3 REVENUE SHARE ANALYSIS
10.4 MARKET SHARE ANALYSIS
10.5 COMPANY EVALUATION MATRIX : CRISPR MARKET
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.6 COMPANY EVALUATION MATRIX: START-UPS/SMES
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
10.7 COMPETITIVE BENCHMARKING OF START-UPS/SMES
10.9 COMPETITIVE SCENARIO AND TRENDS
10.9.1 PRODUCT & SERVICE LAUNCHES
10.9.2 DEALS
10.9.3 OTHER DEVELOPMENTS

11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 THERMO FISHER SCIENTIFIC
11.1.2 MERCK KGAA
11.1.3 AGILENT TECHNOLOGIES
11.1.4 GENSCRIPT
11.1.5 CRISPR THERAPEUTICS AG
11.1.6 EDITAS MEDICINE
11.1.7 INTELLIA THERAPEUTICS
11.1.8 BEAM THERAPEUTICS INC.
11.1.9 CARIBOU BIOSCIENCES, INC.
11.1.10 LONZA GROUP
11.1.11 DANAHER CORPORATION
11.1.12 PERKINELMER
11.1.13 HERA BIOLABS
11.1.14 ORIGENE TECHNOLOGIES, INC.
11.1.15 CELLECTA, INC.
11.2 OTHER PLAYERS
11.2.1 MAMMOTH BIOSCIENCES INC.
11.2.2 APPLIED STEMCELL
11.2.3 NEW ENGLAND BIOLABS INC.
11.2.4 TOOLGEN INC.
11.2.5 GENECOPOEIA, INC.
11.2.6 TWIST BIOSCIENCE CORPORATION
11.2.7 SYNTHEGO CORPORATION
11.2.8 EGENESIS
11.2.9 INSCRIPTA, INC.
11.2.10 PRECISION BIOSCIENCES, INC.

12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS